Nykode Therapeutics AS (CHIX:NYKDo)
kr 18.69 0 (0%) Market Cap: 2.06 Bil Enterprise Value: 666.43 Mil PE Ratio: 0 PB Ratio: 1.28 GF Score: 57/100

Nykode Therapeutics AS at Jefferies Healthcare Conference Transcript

Jun 08, 2022 / 06:30PM GMT
Unidentified Analyst

Hello, everybody, good afternoon. I'd like to welcome you all again back to the 2022 Jefferies Healthcare Conference.

My name [Zed Zucker] and it is my pleasure today to be able to present to you, Michael Engsig and Agnete Fredriksen from Nykode. So I will pass it off to them.

Michael Engsig
Nykode Therapeutics AS - CEO

Thank you very much. Once again, thanks for hosting us here at Jefferies. Pleased to be back.

Sure, you're all familiar with our forward-looking statements. So on that assumption, we'll move forward. I'm pleased to have with me here today, Agnete, our Co-Founder and Chief Innovation and Strategy Officer. I'm Michael Engsig, CEO of Nykode Therapeutics.

So for those of you who are not familiar with Nykode Therapeutics, Nykode is a clinical-stage immunotherapy company entirely focused on exploring and exploiting our proprietary immunotherapy platform, which uniquely targets the antigen presenting cells, which in turn results in a fast strong and long-lasting immune response.

We have a healthy mix

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot